0.00Open0.00Pre Close0 Volume0 Open Interest5.00Strike Price0.00Turnover588.34%IV-1240.48%PremiumJan 17, 2025Expiry Date4.63Intrinsic Value100Multiplier25DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.8306Delta0.4967Gamma0.08Leverage Ratio-0.0026Theta-0.0015Rho-0.07Eff Leverage0.0002Vega
IGC Pharma Stock Discussion
IGC Pharma Advances IGC-AD1 as a Potential Alzheimer's Therapy Addressing Cognitive Impairment and Underlying Disease Pathology
Monday, 2nd December at 8:30 am
New trials to evaluate IGC-AD1's potential impact on amyloid plaque, tau tangles, and cognitive decline in Alzheimer's disease
Expanded research positions IGC-AD1 as a potential treatment targeting the underlying disease pathology of Alzheimer's
POTOMAC, MARYLAND / ACCESSWIRE / December 2, 2024 / IGC Pharma, Inc....
Benzinga· 11 mins ago
The Drug Enforcement Administration (DEA) and the proh...
IGC Pharma Announces Additional Phase 2 Interim Results Highlighting Cognitive Benefits of IGC-AD1 for Alzheimer's Treatment
Interim results indicate cognitive improvement in the active treatment group compared to placebo
- No serious adverse events or deaths reported in the trial
IGC Pharma, Inc. (NYSE:IGC) ("IGC Pharma" or the "Company") today announced additional interim data from its ongoing Phase 2 clinical trial evaluating IGC-AD1. The trial focuses on agitation in...
IGC Pharma Announces Additional Phase 2 Interim Results Highlighting Cognitive Benefits of IGC-AD1 for Alzheimer's Treatment
Legislative Committee In Ireland Calls For Marijuana Legalization And Decriminalization Of 'All Illicit Drugs'" - Marijuana Moment
Benzinga· 2 mins ago
After lawmakers in Ireland delayed a vote on marijuana legalization earlier this year in favor of further studying the issue, a special legislative committee on drug policy has published an interim report with nearly 60 re...
IGC Pharma Announces Patient Enrollment at Toronto's Baycrest in Phase 2 Trial Investigating IGC-AD1
IGC Pharma (NYSE American:IGC) has announced the enrollment of patients at Baycrest Academy for Research and Education in Toronto, Canada, for its ongoing Phase 2 trial of IGC-AD1, a treatment for agitation in Alzheimer's dementia. IGC-AD1 is a partial CB1 receptor agonist with anti-neuroinflammatory properties, targeting key pathways involved in Alzheimer's disease patho...
No comment yet